TELA Bio (NASDAQ:TELA) Given New $2.00 Price Target at Lake Street Capital

TELA Bio (NASDAQ:TELA) had its price objective lowered by Lake Street Capital from $3.00 to $2.00 in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also weighed in on TELA. Canaccord Genuity Group lowered their target price on shares of TELA Bio from $4.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday. Loop Capital set a $3.00 price objective on shares of TELA Bio in a research report on Monday, December 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TELA Bio in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $2.60.

TELA Bio Trading Down 9.4%

TELA opened at $0.69 on Wednesday. The stock has a market capitalization of $27.84 million, a PE ratio of -0.83 and a beta of 0.88. TELA Bio has a one year low of $0.62 and a one year high of $2.20. The company has a debt-to-equity ratio of 26.65, a quick ratio of 2.62 and a current ratio of 3.30. The business’s 50 day moving average price is $0.85 and its 200 day moving average price is $1.14.

TELA Bio (NASDAQ:TELA) last posted its earnings results on Tuesday, March 24th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. TELA Bio had a negative return on equity of 396.31% and a negative net margin of 48.37%.The company had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $21.04 million. As a group, equities research analysts expect that TELA Bio will post -1.37 EPS for the current year.

Hedge Funds Weigh In On TELA Bio

Several institutional investors have recently modified their holdings of the business. WealthTrust Axiom LLC purchased a new position in TELA Bio in the second quarter valued at $40,000. Stonepine Capital Management LLC increased its position in shares of TELA Bio by 1.4% in the 2nd quarter. Stonepine Capital Management LLC now owns 2,083,762 shares of the company’s stock valued at $4,042,000 after purchasing an additional 28,537 shares during the last quarter. Embree Financial Group increased its position in shares of TELA Bio by 695.1% in the 4th quarter. Embree Financial Group now owns 111,318 shares of the company’s stock valued at $131,000 after purchasing an additional 97,318 shares during the last quarter. Citadel Advisors LLC raised its holdings in shares of TELA Bio by 161.3% in the 3rd quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock valued at $53,000 after purchasing an additional 21,781 shares in the last quarter. Finally, Susquehanna International Group LLP lifted its position in shares of TELA Bio by 551.2% during the 3rd quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after purchasing an additional 72,594 shares during the last quarter. Institutional investors and hedge funds own 94.35% of the company’s stock.

TELA Bio News Summary

Here are the key news stories impacting TELA Bio this week:

• Positive Sentiment: Q4 EPS slightly beat estimates: TELA reported GAAP EPS around ($0.16), modestly better than consensus (~$0.18) — a small beat that can be seen as stabilizing after prior losses. Earnings release & transcript
• Positive Sentiment: Management targets growth in 2026: the company is guiding to at least ~8% revenue growth for 2026 while pursuing a commercial transformation — a constructive forward signal if execution holds. Guidance article
• Positive Sentiment: Some analysts remain bullish: Lake Street and Canaccord kept buy ratings (while lowering price targets to $2.00), signaling continued upside expectations from certain brokerages. Canaccord/Lake Street note
• Neutral Sentiment: Revenue roughly in line / mixed read: Q4 revenue was $20.87M vs. consensus ~$21.04M — effectively flat to a slight miss, leaving mixed interpretation depending on margin trends and execution. Press release
• Neutral Sentiment: Readouts and call transcripts available: investors can review the full earnings release and multiple call transcripts for details on commercial initiatives and margin outlook. Earnings call transcript
• Neutral Sentiment: Trading activity is elevated: intraday volume is well above recent average — higher volume often amplifies price moves and reflects stronger investor attention (could be either direction).
• Negative Sentiment: Analysts cut forecasts / price-target trims: multiple firms adjusted models after the quarter — Piper Sandler cut its target to $1.00 and moved to Neutral; Benzinga and other coverage describe broader analyst downward revisions. This reduces near-term upside consensus. Analyst cuts article
• Negative Sentiment: Profitability & balance-sheet metrics remain challenging: the company still posts negative net margins and very high negative ROE; debt-to-equity and small market cap increase execution and volatility risk for investors. Zacks coverage
• Negative Sentiment: Short-interest reports show anomalous data: multiple notices flagged a “large increase” but reported zero/NaN figures — treat these data as unreliable until clarified; a true rise in short interest would be bearish.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.